Thalassemia Clinical Trial
Official title:
Zinc and Bone Metabolism in Thalassemia
The purpose of this study is to test whether zinc can improve bone health in young patients with thalassemia.
The primary aim of this study is to determine if zinc supplementation improves bone health in young patients with thalassemia. Osteoporosis is a significant co-morbidity in patients with thalassemia which leads to decreased quality of life. The most effective way to prevent osteoporosis is to build strong, dense bones in the early years. A combination of disease, endocrine and nutritional factors likely contribute to the etiology of osteoporosis in this population. However, even well transfused patients with normal gonadal function who are supplemented with calcium have low bone mass. It is hypothesized that patients with thalassemia have low bone mass, in part, due to zinc deficiency. Sub-optimal zinc status has been identified in patients with thalassemia and zinc supplementation has been shown to improve linear growth. To test the primary hypothesis, an 18 month randomized placebo-controlled trial of zinc supplementation (25 mg Zn/day) vs. placebo will be conducted in 60 young patients (6-30 yrs) with thalassemia and low bone mass (spine BMD Z-score <-1.0). Bone health, as estimated from measurements of bone mass (by DXA and pQCT) and markers of bone formation and resorption will be the primary outcome variables. This will be the first study to examine the effects of zinc. supplementation on bone health in patients with thalassemia. If zinc supplementation is found to have a clinically important effect, this simple, safe, non-invasive therapy could quickly become a part of the standard care of these young patients and improve overall health in children and adult patients with thalassemia ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
| Completed |
NCT04614779 -
Long-term Clinical Study of CN128 in Thalassemia Patients
|
Phase 2 | |
| Completed |
NCT01158794 -
Genes Influencing Iron Overload State
|
||
| Recruiting |
NCT02995707 -
The Effective and Safety of Thalidomide in NTDT
|
Phase 2 | |
| Active, not recruiting |
NCT01935661 -
A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
|
||
| Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
| Completed |
NCT00901199 -
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
|
Phase 2 | |
| Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
| Active, not recruiting |
NCT03655678 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05508932 -
Atrial Fibrillation in Beta-Thalassemia
|
||
| Completed |
NCT03609827 -
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
|
||
| Completed |
NCT03117192 -
Zinc Supplementation on Cellular Immunity in Thalassemia Major
|
Phase 4 | |
| Completed |
NCT03095326 -
Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia
|
Phase 4 | |
| Completed |
NCT01443312 -
Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
|
||
| Completed |
NCT00744692 -
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
|
Phase 1 | |
| Completed |
NCT00235391 -
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
|
Phase 3 | |
| Not yet recruiting |
NCT06058260 -
Assessment of Cognitive Function and Quality of Life in Thalassemic Children at Sohag University Hospital
|
||
| Completed |
NCT05529550 -
Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children
|
||
| Completed |
NCT04582110 -
The Role of OCTA in Patients Affected by Beta Thalassemia
|
||
| Recruiting |
NCT06213402 -
RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
|